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Bone acidic glycoprotein-75 (BAG-75) is a secreted product of osteoblastic cells 
localized predominantly to areas of new bone formation.   We have identified the 
N-terminal sequence of BAG-75 as LPVARYQNTEEEE and shown that anti-
peptide antibodies against residues #3-13 only recognize the 75 kDa precursor 
and apparent 50 kDa fragment in serum and in osteoblastic cultures.  Formation 
of the 50 kDa fragment is blocked by AEBSF, a serine protease inhibitor which 
we also showed blocks mineralization in osteoblastic cultures.  Measurement of 
BAG-75 and its fragment concentration in serum represents a new method to 
estimate the rate of new bone formation in vivo.  Our purpose was to establish an 
anti-VARYQNTEEEE peptide antibody based ELISA test to measure cross-
reactive proteins released from bone into blood.  Western blotting was performed 
using young rat serum from different ages, rats subjected to ovariectomy (OVX) 
or sham surgery, and normal human serum.  Immunoreactive 50 kDa fragment 
peaked at 18 days after birth which parallels bone formation.  Ovariectomized 
rats displayed a peak of 50 kDa immunoreactivty at 21 days after surgery which 
corresponds to a spike in bone formation in this model (~2.5-fold above controls). 
Comparable assays for osteocalcin showed only a 39% increase.  Also, human 
serum contains a 50 kDa protein which cross-reacts with anti-VARYQNTEEEE 
antibodies.  We then established a competitive 96-well ELISA using anti-peptide 
antibody and new sera at 21 days from ovariectomized or sham rats, a model for 
stimulated bone formation.  VARYQNTEEEE peptide conjugated to keyhole 
limpet hemocyanin (KLH) was used as the bound antigen.  KLH-peptide amount, 
primary antibody concentration, secondary antibody concentration, and blocking 
agent were optimized in a series of experiments.  Optimal conditions were 
determined to be 2 µg input KLH-peptide per well, 1/5,000 dilution of primary 
anti-VARYQNTEEEE antibody, 1/10,000 dilution of secondary antibody, and 
gelatin as a blocking agent.  Sera from OVX rats and sham-operated controls 
were compared to the standard curve (r = 0.9923) created with free KLH-peptide 
as competitor to determine the equivalent amount of KLH-peptide present.  OVX 
sera (n=3) contained an average 2.6 x 10-4 (+/- 1.4 x 10-4) µg peptide equivalent 
versus 1.05 x 10-4 (+/- 0.68 x 10-4) µg for sham sera (n=3).  The difference was 
not significant (t-test, p=0.157), however, doubling the sample size is predicted to 
yield significance.   Conclusions:  A. Cross-reactive 75 kDa and 50 kDa proteins 
are present in human and rat serum and increase in concentration when bone 
formation is stimulated.  B. A new, single antibody based ELISA assay was 
established to quantitate antigen released from bone into blood.  C. In contrast to 
other commercial bone formation assays (collagen peptides and osteocalcin), the 
size of cross-reactive protein (>50 kDa) should preclude kidney filtration and 
facilitate measurement.  D. This serum biomarker undergoes a 2-3 fold average 
increase within 3 weeks after simulation of bone.  This test may be useful to 
monitor the early response to stimulatory therapy in osteoporosis patients or to 
repressive glucocorticoid therapy in sarcoidosis patients.  Currently, a 1% 
change in bone mineral density requires 12-18 months to detect by x-ray 
methods. 
